BioDelivery Sciences International, Inc.  

(Public, NASDAQ:BDSI)   Watch this stock  
Find more results for BDSI
2.95
+0.10 (3.51%)
Jun 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.80 - 3.05
52 week 1.50 - 3.10
Open 2.95
Vol / Avg. 1.24M/845,760.00
Mkt cap 168.94M
P/E     -
Div/yield     -
EPS -0.03
Shares 55.33M
Beta 1.19
Inst. own 45%
Aug 7, 2017
Q2 2017 BioDelivery Sciences International Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 30, 2017
BioDelivery Sciences International Inc Annual Shareholders Meeting (Estimated) - 11:00AM EDT - Add to calendar
Jun 13, 2017
BioDelivery Sciences International Inc at William Blair Growth Stock Conference
Jun 6, 2017
BioDelivery Sciences International Inc at Jefferies Healthcare Conference
May 15, 2017
Q1 2017 BioDelivery Sciences International Inc Earnings Call - Webcast
May 15, 2017
Q1 2017 BioDelivery Sciences International Inc Earnings Release
May 3, 2017
BioDelivery Sciences International Inc at Deutsche Bank Health Care Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 163.94% -431.87%
Operating margin 119.54% -411.26%
EBITD margin - -402.02%
Return on average assets 242.42% -86.58%
Return on average equity 1886.43% -957.27%
Employees 99 -
CDP Score - -

Address

4131 Parklake Ave Ste 225
RALEIGH, NC 27612-2390
United States - Map
+1-919-5829050 (Phone)
+1-919-5829051 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

Officers and directors

Frank E. O'Donnell Jr., M.D. Executive Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Mark A. Sirgo Pharm.D. President, Chief Executive Officer, Vice Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Ernest R. De Paolantonio CPA Chief Financial Officer, Treasurer, Secretary
Age: 63
Bio & Compensation  - Reuters
Niraj Vasisht Ph.D. Senior Vice President of Product Development and Chief Technical Officer
Age: 52
Bio & Compensation  - Reuters
Peter L. Ginsberg Vice President - Business Development
Bio & Compensation  - Reuters
William B. Stone Lead Independent Director
Age: 73
Bio & Compensation  - Reuters
Timothy C. Tyson Director
Age: 62
Bio & Compensation  - Reuters
Charles J. Bramlage Independent Director
Age: 55
Bio & Compensation  - Reuters
Thomas W. D'Alonzo Independent Director
Age: 72
Bio & Compensation  - Reuters
Barry I. Feinberg M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters